anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Iloprost
Trial phase: Not Applicable
ATC code: B01AC11
SMILES: CC#CCC(C)C(O)C=CC1C(O)CC2CC(=CCCCC(=O)O)CC21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.

Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
Eligibility criteria:
Inclusion Criteria:

Age greater than or equal to 18 years old
Congenital heart disease with pulmonary arterial hypertension and cyanosis (resting oxygen saturation < 90% on room air)
Stable on oral therapy (PDE5 inhibitor and/or endothelin blockade) for at least three months

Exclusion Criteria:

Age < 18 years old
Current intravenous or subcutaneous prostacyclin therapy
Resting Systemic Hypotension (Systolic blood pressure < 85 mmHg)
Women who are pregnant or may become pregnant (unwilling to utilize effective contraception), as well as nursing mothers
Inability to ambulate
Planned surgical procedure during the study period
Intervention: Ubidecarenone
Trial phase: Phase 2
ATC code: C01EB09
SMILES: COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.

Coenzyme Q10: Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
Eligibility criteria:
Inclusion Criteria:

Adult patients (age > 18 years)
Comatose after CA with subsequent return of spontaneous circulation

Exclusion Criteria:

Comatose status prior to CA
CoQ10 therapy within one month prior to CA
Pregnancy
Intervention: Calcitriol
Trial phase: Phase 3
ATC code: A11CC04 | D05AX03
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 43
Group description: Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
Eligibility criteria:
Inclusion Criteria:

25(OH)D < 20 ng/mL OR Uric acid ≥ 5 mg/dL
Age ≥ 18, ≤ 75 years
Body Mass Index (BMI) ≥ 25 kg/m^2

Exclusion Criteria:

Hypertension, or on BP-lowering medicine
Diabetes
Coronary Heart Disease
estimated glomerular filtration rate (EGFR) <60 mL/min
Kidney stones
Active cancer (except non-melanoma skin cancer)
Pregnant
Taking vitamin D supplements and unwilling to stop
Osteoporosis
Hypo- or hypercalcemia
Hypo- or hyperphosphatemia
Known allergy to angiotensin-converting enzyme (ACE)-inhibitors
Taking medication for hyperuricemia
Gout, anemia, cirrhosis, active/chronic hepatitis, abnormal aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin levels, or anemia
Known allergy to either allopurinol or probenecid
Current use of didanosine, azothioprine, methotrexate, ketoprofen, ketorolac, mycophenolate, or ACE-inhibitors
Intervention: Probenecid
Trial phase: Phase 3
ATC code: G01AE10 | M04AB01
SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 46
Group description: Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
Eligibility criteria:
Inclusion Criteria:

25(OH)D < 20 ng/mL OR Uric acid ≥ 5 mg/dL
Age ≥ 18, ≤ 75 years
Body Mass Index (BMI) ≥ 25 kg/m^2

Exclusion Criteria:

Hypertension, or on BP-lowering medicine
Diabetes
Coronary Heart Disease
estimated glomerular filtration rate (EGFR) <60 mL/min
Kidney stones
Active cancer (except non-melanoma skin cancer)
Pregnant
Taking vitamin D supplements and unwilling to stop
Osteoporosis
Hypo- or hypercalcemia
Hypo- or hyperphosphatemia
Known allergy to angiotensin-converting enzyme (ACE)-inhibitors
Taking medication for hyperuricemia
Gout, anemia, cirrhosis, active/chronic hepatitis, abnormal aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin levels, or anemia
Known allergy to either allopurinol or probenecid
Current use of didanosine, azothioprine, methotrexate, ketoprofen, ketorolac, mycophenolate, or ACE-inhibitors
Intervention: Resveratrol
Trial phase: Phase 1 | Phase 2
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Intervention

Resveratrol: The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
Eligibility criteria:
Inclusion Criteria:

Boxers between the ages 18-35 years old
Both men and women
Boxers with an estimated concussion (Mild and Moderate) as estimated by the on-site physician or athletic trainer
Subject has provided full written informed consent prior to the performance of any protocol-specified procedure

Exclusion Criteria:

Immediate hospitalization for sports-related concussion (Severe Concussion)
Known inclusion in an interventional clinical trial
Patients with metal implants that would interfere with the MRI scan
Known anemia
Known Pregnancy
Known history of alcohol/drug abuse
Intervention: Vancomycin
Trial phase: Phase 1
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Oral Vancomycin is commercially available (Vancocin, ViroPharma Inc.) for treatment of gastrointestinal infection such as, Clostridium difficile infection. In fact, our published observation of using oral vancomycin in treating PSC was an incidental finding to our treatment for Cl. Difficile gastrointestinal infection in a child with PSC (J Pediatr Gastroenterol Nutr 27:580-3, 1998). Since oral vancomycin is poorly absorbed, no serious adverse events were anticipated in this study.
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of biliary atresia or primary sclerosing cholangitis.
Clinical controls who are undergoing upper endoscopy or colonoscopy and do not have biliary atresia or primary sclerosing cholangitis.
Subjects who have been on oral vancomycin for 1 year for biliary atresia or -

Exclusion Criteria:

Patients that have taken antibiotics within the last 3 month will be excluded as this will alter the original bacterial flora.
Intervention: Metronidazole
Trial phase: Not Applicable
ATC code: A01AB17 | A02BD01 | A02BD02 | A02BD03 | A02BD08 | A02BD11 | A02BD13 | A02BD15 | D06BX01 | G01AF01 | G01AF20 | J01RA03 | J01RA04 | J01RA10 | J01RA14 | J01XD01 | P01AB01 | P01AB51 | P01AB52
SMILES: Cc1ncc([N+](=O)[O-])n1CCO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.

Metronidazole: Metronidazole 500mg orally twice daily for seven days
Eligibility criteria:
Inclusion Criteria:

Women who are actively trying to conceive via intrauterine insemination or in vitro fertilization

Exclusion Criteria:

Current use of an oral or vaginal antibiotic.
History of allergy or adverse reaction to metronidazole.
Prior enrollment in study (patients returning for repeat cycle may not be re-enrolled).
Intervention: Erythromycin
Trial phase: Phase 2
ATC code: D10AF02 | D10AF52 | J01FA01 | S01AA17
SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: 200mg/5ml elixir administered orally three times a day half an hour prior to meals.

Erythromycin: 200mg/5ml elixir administered orally three times a day half an hour prior to meals.
Eligibility criteria:
Inclusion Criteria:

presenting to gastroenterology motility specialty clinics at the University of Florida (UF), who meet the clinical and radiologic diagnostic criteria for diagnosis of GP

Exclusion Criteria:

Any history of mechanical obstruction
Gastrointestinal malignancy
Current use of prokinetics such as cisapride, pimozide, or anticholinergic medication which cannot be discontinued 72 hrs prior to study
Abnormal upper endoscopy with finding of erosions or ulcerations
Helicobacter pylori infection in past 6 months
Recent abdominal surgery < 6 months
Cardiac history with EKG finding of QTC > 450 done on a screening test
Detected renal or hepatic dysfunction described as a GFR <10 ml/min and ALT/AST values > 2 times the normal level in our laboratory
Allergy to macrolide antibiotics
Psychiatric history other than anxiety or depression
Predominant symptoms of irritable bowel syndrome such as constipation or diarrhea
Uncontrolled diabetes with fasting blood glucose levels > 180 mg/dL, due to effect of hyperglycemia on gastric emptying. For patients with diabetes, blood glucose levels will be recorded in a patient diary.
Pregnant or nursing females
Any history of myasthenia gravis
Current use of Coumadin, lovastatin, simvastatin Nelfinavir, theophylline, digoxin, ergotamine/dihydroergotamine products, benzodiazepines, and sildenafil (this will be discontinued for the duration of the clinical trial if subject is on this medication).
History of elevated liver function studies or CPKs.
Pregnancy : A urine pregnancy test will be performed at the beginning of each treatment period and only subjects who are not pregnant will be enrolled for the study.
Intervention: Azithromycin
Trial phase: Phase 2
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: The dose of Azithromycin given was previously determined based on our dose-response analysis in 10 healthy subjects to be 50 mg. The total daily dosage of Azithromycin given therefore was 150 mg which was divided three times daily and administered as 50mg/5ml given three times a day as elixir orally, similar to the erythromycin volume.
Eligibility criteria:
Inclusion Criteria:

presenting to gastroenterology motility specialty clinics at the University of Florida (UF), who meet the clinical and radiologic diagnostic criteria for diagnosis of GP

Exclusion Criteria:

Any history of mechanical obstruction
Gastrointestinal malignancy
Current use of prokinetics such as cisapride, pimozide, or anticholinergic medication which cannot be discontinued 72 hrs prior to study
Abnormal upper endoscopy with finding of erosions or ulcerations
Helicobacter pylori infection in past 6 months
Recent abdominal surgery < 6 months
Cardiac history with EKG finding of QTC > 450 done on a screening test
Detected renal or hepatic dysfunction described as a GFR <10 ml/min and ALT/AST values > 2 times the normal level in our laboratory
Allergy to macrolide antibiotics
Psychiatric history other than anxiety or depression
Predominant symptoms of irritable bowel syndrome such as constipation or diarrhea
Uncontrolled diabetes with fasting blood glucose levels > 180 mg/dL, due to effect of hyperglycemia on gastric emptying. For patients with diabetes, blood glucose levels will be recorded in a patient diary.
Pregnant or nursing females
Any history of myasthenia gravis
Current use of Coumadin, lovastatin, simvastatin Nelfinavir, theophylline, digoxin, ergotamine/dihydroergotamine products, benzodiazepines, and sildenafil (this will be discontinued for the duration of the clinical trial if subject is on this medication).
History of elevated liver function studies or CPKs.
Pregnancy : A urine pregnancy test will be performed at the beginning of each treatment period and only subjects who are not pregnant will be enrolled for the study.
Intervention: Celecoxib
Trial phase: Not Applicable
ATC code: C08CA51 | G01AE10 | L01XX33 | M01AH01 | N02AJ16
SMILES: Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 78
Group description: Patients received celecoxib
Eligibility criteria:
Inclusion Criteria:

>/= 18 years old
Male
Scheduled to undergo microdissection testicular sperm extraction

Exclusion Criteria:

History of allergies to celecoxib (Celecoxib)
Renal failure
History of ulcer disease
Any history of myocardial infarction
Any history of stroke
History of bleeding diathesis
Use of aspirin
Intervention: Preladenant
Trial phase: Phase 1
SMILES: COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
Eligibility criteria:
Inclusion Criteria:

Has a body mass index (BMI) between 19 to 34 kg/m^2, inclusive
Has mild to severe CRI and not on dialysis (Participants with normal renal function are to be matched to subjects with renal impairment)
Clinical laboratory tests, electrocardiogram, and vital signs within normal ranges
Free of any clinically significant disease that would interfere with the study evaluations (except related to his/her renal disease and comorbid conditions)

Exclusion Criteria:

Females who are pregnant, intend to become pregnant (within 3 months of ending the study), or are nursing/breastfeeding
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
Had a renal transplant or are on dialysis
Has a history of any infectious disease within 4 weeks
Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
Has donated blood or had a blood transfusions in the past 60 days
Has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which could interfere with their ability to participate in the trial
Has a history of malignancy
Has evidence of suicidality or is at risk for self-harm or harm to others
Intervention: Preladenant
Trial phase: Phase 1
SMILES: COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
Eligibility criteria:
Inclusion Criteria:

Has a body mass index (BMI) between 19 to 34 kg/m^2, inclusive
Has mild to severe CRI and not on dialysis (Participants with normal renal function are to be matched to subjects with renal impairment)
Clinical laboratory tests, electrocardiogram, and vital signs within normal ranges
Free of any clinically significant disease that would interfere with the study evaluations (except related to his/her renal disease and comorbid conditions)

Exclusion Criteria:

Females who are pregnant, intend to become pregnant (within 3 months of ending the study), or are nursing/breastfeeding
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
Had a renal transplant or are on dialysis
Has a history of any infectious disease within 4 weeks
Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
Has donated blood or had a blood transfusions in the past 60 days
Has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which could interfere with their ability to participate in the trial
Has a history of malignancy
Has evidence of suicidality or is at risk for self-harm or harm to others
Intervention: Preladenant
Trial phase: Phase 1
SMILES: COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
Eligibility criteria:
Inclusion Criteria:

Has a body mass index (BMI) between 19 to 34 kg/m^2, inclusive
Has mild to severe CRI and not on dialysis (Participants with normal renal function are to be matched to subjects with renal impairment)
Clinical laboratory tests, electrocardiogram, and vital signs within normal ranges
Free of any clinically significant disease that would interfere with the study evaluations (except related to his/her renal disease and comorbid conditions)

Exclusion Criteria:

Females who are pregnant, intend to become pregnant (within 3 months of ending the study), or are nursing/breastfeeding
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
Had a renal transplant or are on dialysis
Has a history of any infectious disease within 4 weeks
Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
Has donated blood or had a blood transfusions in the past 60 days
Has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which could interfere with their ability to participate in the trial
Has a history of malignancy
Has evidence of suicidality or is at risk for self-harm or harm to others
Intervention: Preladenant
Trial phase: Phase 1
SMILES: COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
Eligibility criteria:
Inclusion Criteria:

Has a body mass index (BMI) between 19 to 34 kg/m^2, inclusive
Has mild to severe CRI and not on dialysis (Participants with normal renal function are to be matched to subjects with renal impairment)
Clinical laboratory tests, electrocardiogram, and vital signs within normal ranges
Free of any clinically significant disease that would interfere with the study evaluations (except related to his/her renal disease and comorbid conditions)

Exclusion Criteria:

Females who are pregnant, intend to become pregnant (within 3 months of ending the study), or are nursing/breastfeeding
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
Had a renal transplant or are on dialysis
Has a history of any infectious disease within 4 weeks
Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
Has donated blood or had a blood transfusions in the past 60 days
Has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which could interfere with their ability to participate in the trial
Has a history of malignancy
Has evidence of suicidality or is at risk for self-harm or harm to others
Intervention: Preladenant
Trial phase: Phase 1
SMILES: COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
Eligibility criteria:
Inclusion Criteria:

Has a body mass index (BMI) between 19 to 34 kg/m^2, inclusive
Has mild to severe CRI and not on dialysis (Participants with normal renal function are to be matched to subjects with renal impairment)
Clinical laboratory tests, electrocardiogram, and vital signs within normal ranges
Free of any clinically significant disease that would interfere with the study evaluations (except related to his/her renal disease and comorbid conditions)

Exclusion Criteria:

Females who are pregnant, intend to become pregnant (within 3 months of ending the study), or are nursing/breastfeeding
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
Had a renal transplant or are on dialysis
Has a history of any infectious disease within 4 weeks
Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
Has donated blood or had a blood transfusions in the past 60 days
Has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which could interfere with their ability to participate in the trial
Has a history of malignancy
Has evidence of suicidality or is at risk for self-harm or harm to others
Intervention: ORM-12741
Trial phase: Phase 2
SMILES: COC[C@@]1(C)CCCN2CCc3c(oc4ccccc34)[C@@H]21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: ORM-12741: 60mg twice a day
Eligibility criteria:
Inclusion Criteria:

Informed consent obtained from the patient and legally acceptable representative, if required
Informed consent obtained from the caregiver
Males and and females between 55-90 years
Diagnosis of probable Alzheimer's disease, history of progressive cognitive deterioration
Brain imaging consistent with Alzheimer's disease
Mini-mental state examination score 12-21
Treated with donepezil, rivastigmine or galantamine
At least mild level of behavioral symptoms

Exclusion Criteria:

Other types of dementias
Modified Hachinski Ischemia Score > 4
Use of memantine, antipsychotics, anticholinergic medication and benzodiazepines (at a max of 3 nights/week) within 2 months
Changes in antidepressant dosing within 2 months
Use of other psychotropic agents
Myocardial infarction within the past 2 years
Malignancy within the past 5 years
Suicidal ideation, risk of suicide
History of alcoholism or drug abuse within 5 years
Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness
Specific findings in brain imaging
Abnormal findings in heart rate, blood pressure, ECG, laboratory tests, physical examination; orthostatic hypotension
Blood donation or participation in a drug study within 60 days
Previous AD immunotherapy treatment
Patient cannot complete the computerised cognitive training
Patients who reside in a skilled nursing facility
Patients who are not able to swallow capsules